Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Clarivate’s fair value price target has been reset from US$4.61 to US$3.61, signalling that analysts now see a lower implied upside than before. This shift lines up with recent research that keeps ratings spread from Underweight to Buy, while questioning how much credit to give management for planned portfolio changes and potential AI related risks. As you read on, you will see how to track these moving parts and what to watch as the Clarivate story continues to evolve.
Stay updated as the Fair Value for Clarivate shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Clarivate.
-
Stifel, which maintains a Buy rating with its price target moved to US$6 from US$7, signals that some research still sees upside potential relative to several peers on the Street.
-
RBC Capital highlights solid free cash flow and guidance pointing to about 10% free cash flow growth at the FY26 midpoint. This supports the view that Clarivate’s cash generation gives it room to keep working on its portfolio plans.
-
Several firms have cut targets into the US$2 to US$3 range, including Citi at US$2.80, Goldman Sachs at US$3.10 and RBC Capital at US$3, pointing to more cautious expectations around valuation.
-
RBC Capital and Barclays both flag execution risk around a potential sale of the Life Sciences and Healthcare segment. RBC also cites ongoing AI disintermediation risk as a key concern for Clarivate’s long term positioning.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 1 risk for Clarivate. See which could impact your investment.
-
Clarivate launched the Clarivate AI50 report, a data driven benchmark identifying 50 organizations leading in high impact AI inventions, with many also included in the Top 100 Global Innovators 2026.
-
The AI50 analysis draws on the Clarivate Center for IP and Innovation Research and the proprietary Derwent Strength Index to assess the influence, rarity and investment behind AI related patents across countries and industry segments.
-
Clarivate is integrating Cortellis Regulatory Intelligence data with Anthropic’s Claude via the Model Context Protocol, giving life sciences customers context aware access to regulatory information inside existing AI workflows.
-
The new CRI MCP connection allows Clarivate CRI and Claude customers to build agents that combine Clarivate regulatory content with internal data, supporting regulatory monitoring and decision making automation, while full year 2026 guidance points to revenues of US$2.30b to US$2.42b and a net loss of US$189 million to US$124 million.